Organization
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China
5 abstracts
Abstract
Real-world data of efficacy and safety of denosumab on patients with breast cancer with bone metastasis: Results from Chinese clinical experience.Org: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China,
Abstract
Tucidinostat plus toripalimab in patients with unresectable or metastatic melanoma: An open-label, single-arm phase II study.Org: Department of Melanoma and Sarcoma Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Department of Genitourinary Oncology, Melanoma Institute Australia, Sydney, Australia,
Abstract
Use of integrated multi-omics analysis to determine antitumor efficacy of donafenib in combination with FADS2 inhibition in hepatocellular carcinoma.Org: Beijing Cancer Hospital & Institute, Department of Interventional Therapy, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China,
Abstract
Efficacy and safety of cadonilimab in combination with pulocimab and paclitaxel as second-line therapy in patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer who failed immunochemotherapy: A multicenter, double-blind, randomized trial.Org: Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Department of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Liaoning Cancer Hospital and Institute, Shenyang, China,
Abstract
A multicenter, single-arm, open-label trial of birociclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer.Org: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Harbin Medical University Cancer Hospital, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital, Shenyang, China, Liaoning Cancer Hospital and Institute, Shenyang, China,